Intranasal Ketamine for Late-Life Depression and Suicidal Ideation
Brief Summary
The investigators of this study plan to investigate the feasibility and efficacy of repeated doses of intranasal ketamine in severely depressed patients who are at least 65 years of age and experiencing suicidal ideation. The results of the study could lead to development of new strategies for treating depression.
Condition or Disease
- Depression
- Suicide
- Suicidal Ideation
Phase
Study Design
Study type: | Interventional |
---|---|
Status: | Withdrawn |
Study results: | No Results Available |
Age: | 65 Years and older (Older Adult) |
Enrollment: | 0 () |
Funded by: | Other |
Masking |
Clinical Trial Dates
Start date: | Jul 15, 2020 | |
---|---|---|
Primary Completion: | Jul 15, 2020 | |
Completion Date: | Jul 15, 2020 | |
Study First Posted: | Nov 20, 2014 | |
Results First Posted: | Aug 31, 2020 | |
Last Updated: | Mar 03, 2017 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 65 |
More Details
NCT Number: | NCT02295787 |
---|---|
Other IDs: | 2014D006212 |
Study URL: | https://ClinicalTrials.gov/show/NCT02295787 |
Last updated: Jun 17, 2022